Cargando…

Immunosuppressive Signaling Pathways as Targeted Cancer Therapies

Immune response has been shown to play an important role in defining patient prognosis and response to cancer treatment. Tumor-induced immunosuppression encouraged the recent development of new chemotherapeutic agents that assists in the augmentation of immune responses. Molecular mechanisms that tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Setlai, Botle Precious, Hull, Rodney, Bida, Meshack, Durandt, Chrisna, Mulaudzi, Thanyani Victor, Chatziioannou, Aristotelis, Dlamini, Zodwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945019/
https://www.ncbi.nlm.nih.gov/pubmed/35327484
http://dx.doi.org/10.3390/biomedicines10030682
_version_ 1784673852097298432
author Setlai, Botle Precious
Hull, Rodney
Bida, Meshack
Durandt, Chrisna
Mulaudzi, Thanyani Victor
Chatziioannou, Aristotelis
Dlamini, Zodwa
author_facet Setlai, Botle Precious
Hull, Rodney
Bida, Meshack
Durandt, Chrisna
Mulaudzi, Thanyani Victor
Chatziioannou, Aristotelis
Dlamini, Zodwa
author_sort Setlai, Botle Precious
collection PubMed
description Immune response has been shown to play an important role in defining patient prognosis and response to cancer treatment. Tumor-induced immunosuppression encouraged the recent development of new chemotherapeutic agents that assists in the augmentation of immune responses. Molecular mechanisms that tumors use to evade immunosurveillance are attributed to their ability to alter antigen processing/presentation pathways and the tumor microenvironment. Cancer cells take advantage of normal molecular and immunoregulatory machinery to survive and thrive. Cancer cells constantly adjust their genetic makeup using several mechanisms such as nucleotide excision repair as well as microsatellite and chromosomal instability, thus giving rise to new variants with reduced immunogenicity and the ability to continue to grow without restrictions. This review will focus on the central molecular signaling pathways involved in immunosuppressive cells and briefly discuss how cancer cells evade immunosurveillance by manipulating antigen processing cells and related proteins. Secondly, the review will discuss how these pathways can be utilized for the implementation of precision medicine and deciphering drug resistance.
format Online
Article
Text
id pubmed-8945019
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89450192022-03-25 Immunosuppressive Signaling Pathways as Targeted Cancer Therapies Setlai, Botle Precious Hull, Rodney Bida, Meshack Durandt, Chrisna Mulaudzi, Thanyani Victor Chatziioannou, Aristotelis Dlamini, Zodwa Biomedicines Review Immune response has been shown to play an important role in defining patient prognosis and response to cancer treatment. Tumor-induced immunosuppression encouraged the recent development of new chemotherapeutic agents that assists in the augmentation of immune responses. Molecular mechanisms that tumors use to evade immunosurveillance are attributed to their ability to alter antigen processing/presentation pathways and the tumor microenvironment. Cancer cells take advantage of normal molecular and immunoregulatory machinery to survive and thrive. Cancer cells constantly adjust their genetic makeup using several mechanisms such as nucleotide excision repair as well as microsatellite and chromosomal instability, thus giving rise to new variants with reduced immunogenicity and the ability to continue to grow without restrictions. This review will focus on the central molecular signaling pathways involved in immunosuppressive cells and briefly discuss how cancer cells evade immunosurveillance by manipulating antigen processing cells and related proteins. Secondly, the review will discuss how these pathways can be utilized for the implementation of precision medicine and deciphering drug resistance. MDPI 2022-03-16 /pmc/articles/PMC8945019/ /pubmed/35327484 http://dx.doi.org/10.3390/biomedicines10030682 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Setlai, Botle Precious
Hull, Rodney
Bida, Meshack
Durandt, Chrisna
Mulaudzi, Thanyani Victor
Chatziioannou, Aristotelis
Dlamini, Zodwa
Immunosuppressive Signaling Pathways as Targeted Cancer Therapies
title Immunosuppressive Signaling Pathways as Targeted Cancer Therapies
title_full Immunosuppressive Signaling Pathways as Targeted Cancer Therapies
title_fullStr Immunosuppressive Signaling Pathways as Targeted Cancer Therapies
title_full_unstemmed Immunosuppressive Signaling Pathways as Targeted Cancer Therapies
title_short Immunosuppressive Signaling Pathways as Targeted Cancer Therapies
title_sort immunosuppressive signaling pathways as targeted cancer therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945019/
https://www.ncbi.nlm.nih.gov/pubmed/35327484
http://dx.doi.org/10.3390/biomedicines10030682
work_keys_str_mv AT setlaibotleprecious immunosuppressivesignalingpathwaysastargetedcancertherapies
AT hullrodney immunosuppressivesignalingpathwaysastargetedcancertherapies
AT bidameshack immunosuppressivesignalingpathwaysastargetedcancertherapies
AT durandtchrisna immunosuppressivesignalingpathwaysastargetedcancertherapies
AT mulaudzithanyanivictor immunosuppressivesignalingpathwaysastargetedcancertherapies
AT chatziioannouaristotelis immunosuppressivesignalingpathwaysastargetedcancertherapies
AT dlaminizodwa immunosuppressivesignalingpathwaysastargetedcancertherapies